NORTHAMPTON, MA / ACCESSWIRE / March 1, 2023 / Boston Scientific
Originally published by Medical Device + Diagnostic Industry
Clinical trials are an early step in device and therapy development which have significant impact on the types of products available to patients. The demographics of patients in these trials carries an impact on products, making diversity in clinical trials key to ensure all patient needs are being evaluated, and targeted for treatments. Medtronic and Boston Scientific share the efforts the companies have undertaken to broaden the patients in their clinical trials.
"We cannot provide the best therapies across the world unless we fully represent the range of people who are affected," said Laura Mauri, MD, senior vice president, chief scientific, medical, and regulatory officer at Medtronic. "Diverse representation in our research and development is not only a social imperative that is needed to interrupt the cycle of health inequity, but also a clinical necessity to fully understand our products. Diversity allows us to better reflect the entirety of the population we're trying to serve, improve device efficacy across that entire population, and ultimately improve outcomes for a broader group of patients and communities."
Continue reading here.
Image credit: Ariel Skelley / The Image Bank via Getty Images
View additional multimedia and more ESG storytelling from Boston Scientific on 3blmedia.com.
Contact Info:
Spokesperson: Boston Scientific
Website: https://www.3blmedia.com/profiles/boston-scientific
Email: info@3blmedia.com
SOURCE: Boston Scientific
View source version on accesswire.com:https://www.accesswire.com/741431/Representation-Matters-in-Clinical-Trials
